Market capitalization | HKD54.93b |
Enterprise Value | HKD45.47b |
P/E (TTM) P/E ratio | 8.59 |
EV/Sales (TTM) EV/Sales | 1.33 |
P/S ratio (TTM) P/S ratio | 1.60 |
P/B ratio (TTM) P/B ratio | 1.51 |
Dividend yield | 6.45% |
Last dividend (FY23) | HKD0.30 |
Revenue growth (TTM) Revenue growth | -3.20% |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
28 Analysts have issued a CSPC Pharmaceutical Group Limited forecast:
28 Analysts have issued a CSPC Pharmaceutical Group Limited forecast:
Dec '23 | |
Current assets | 29,446 29,446 |
Fixed assets | 21,511 21,511 |
Total Assets | 50,957 50,957 |
Dec '23 | |
Equity | 38,555 38,555 |
Debt capital | 12,027 12,027 |
Total Capital | 50,582 50,582 |
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Hong Kong.
Head office | Hong Kong |
CEO | Cui Zhang |
Employees | 23,500 |
Founded | 1997 |
Website | www.cspc.com.hk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.